$PULM News
Last published 3d ago
- 3d agoPULMEos SENOLYTIX’s PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International ConferenceGlobeNewswireData to highlight PTC-2105’s attenuation of terminal lean-mass decline and semaglutide-associated lean-mass loss in aged mice PTC-2105 is Eos’s lead clinical candidate in development for elderly patients with
- 1w agoPULMEos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat StudyGlobeNewswireInterim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos’s R&D Facility; Data Support IND-Enabling
- 3w agoPULMEos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived MouseGlobeNewswireIn naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142)"Speedy," a
- 3mo agoPULMPulmatrix Announces Second Quarter 2026 Financial Results and Progress on MergerPR NewswireForm S-4 filed related to the announced merger agreement with Eos SENOLYTIXFRAMINGHAM, Mass., Aug. 13, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a
- 6mo agoPULMPulmatrix Announces First Quarter 2026 Financial ResultsPR NewswirePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled...
- 6mo agoPULMPulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned MergerPR NewswirePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), today announced the closing of its previously announced private placement of Series B...
- 7mo agoPULMPulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve HealthspanPR NewswirePulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix") and Eos SENOLYTIX, Inc. ("Eos"), a biotechnology company developing novel gerotherapeutic peptides...
- 8mo agoPULMPulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger OpportunitiesPR NewswirePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled...
- 8mo agoPULMPulmatrix Announces Year-End and Fourth Quarter 2025 Financial ResultsPR NewswirePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled...
- 10mo agoPULMPulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore AlternativesPR NewswirePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled...
- 1y agoPULMPulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation AssetsPR NewswirePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled...
- 1y agoPULMPulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation AssetsPR NewswirePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled...
- 1y agoPULMPulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for AssetsPR NewswirePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled...
- 1y agoPULMPulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for AssetsPR NewswirePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled...
- 1y agoPULMCullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic PainGlobeNewswireSAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cullgen Inc. ("Cullgen"), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE™ platform to
- 1y agoBCOVBERYPULMROICKuehn Law Encourages BCOV, BERY, ROIC, and PULM Investors to Contact Law FirmGlobeNewswireNEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 1y agoENTOPFCPIKPULMKuehn Law Encourages ENTO, PULM, PIK, and PFC Investors to Contact Law FirmGlobeNewswireNEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 1y agoPULMPulmatrix and Cullgen Announce Proposed MergerPR NewswirePulmatrix, Inc. ("Pulmatrix") (Nasdaq: PULM), a clinical-stage biopharmaceutical company, today announced a merger agreement with Cullgen Inc....
- 2y agoPULMPulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswirePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to...
- 2y agoPULMPulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswirePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to...
- 2y agoPULMMNKDPulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind CorporationPR NewswirePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to...
- 2y agoPULMPulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)PR NewswirePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to...
- 2y agoPULMPulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswirePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to...
- 2y agoPULMPulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate UpdatePR NewswirePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to...
- 2y agoPULMPulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic AlternativesPR NewswirePulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to...
- 3y agoPULMPulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate UpdatePR NewswirePulmatrix, Inc. (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and...
- 3y agoPULMPulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute MigrainePR NewswirePulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE") in the treatment of acute migraine BEDFORD, Mass.,
- 3y agoPULMPulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled ItraconazolePR NewswireResults demonstrate a low likelihood of clinically meaningful drug-drug interactions when PUR1900 is administered with medications contraindicated with oral itraconazole Pulmatrix is currently enrolling patients in a
- 3y agoPULMPulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate UpdatePR NewswireSubject enrollment for the Phase 2b study of PUR1900 is ongoing with five additional sites added during Q2, totaling thirteen active sites to date in four countries, and topline data anticipated in Q3 2024 Submitted an
- 3y agoPULMPulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute MigrainePR NewswireLEXINGTON, Mass., July 11, 2023 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address
- 3y agoPULMPulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache SocietyPR NewswireLEXINGTON, Mass., June 15, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system
- 3y agoPULMPulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International ConventionPR NewswirePresentation will showcase Company's patented iSPERSE™ technology and positive topline results from Phase 1 study of PUR3100 for acute migraine LEXINGTON, Mass., May 24, 2023 /PRNewswire/ -- Pulmatrix, Inc.
- 3y agoPULMPulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate UpdatePR NewswirePatient dosing initiated for Phase 2b study of PUR1900 for ABPA Phase 1 study of PUR3100 for migraine achieves positive topline results $30.8 million in cash and cash equivalents at the end of Q1 2023 providing projected
- 3y agoPULMPulmatrix Supports World Asthma Day 2023PR NewswireLEXINGTON, Mass., May 2, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system
- 3y agoPULMPulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate UpdatePR NewswirePUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in cash and cash equivalents at the end of 2022 providing cash runway
- 3y agoPULMPulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with AsthmaPR NewswireLEXINGTON, Mass., Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented
- 3y agoPULMPulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"PR NewswireLEXINGTON, Mass., Jan. 25, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented
- 3y agoPULMPulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and ImmunologyPR NewswireLEXINGTON, Mass., Jan. 23, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented
- 3y agoPULMPulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute MigrainePR NewswirePUR3100 was safe and all doses had fewer GI side effects compared to IV DHE PUR3100 demonstrated a five-minute Tmax and Cmax within the targeted therapeutic range for all three doses tested LEXINGTON, Mass., Jan. 4, 2023
- 3y agoPULMStudy to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and Allergic Bronchopulmonary Aspergillosis - NCT05667662ClinicalTrials.govIncidence of Treatment Emergent Adverse Events (TEAEs), Safety spirometry assessments, Vital sign measurements, (and 7 more...)
- 4y agoPULMPulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate UpdatePR NewswirePUR1900 (Pulmazole) on track for Phase 2 study start in Q1 2023 PUR3100 Phase 1 study top line data anticipated in early Q1 2023 $40.7 million in cash and cash equivalents at end of Q3 2022 LEXINGTON, Mass., Nov. 10,
- 4y agoPULMPulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate UpdatePR NewswirePulmazole is on track for Phase 2b study start in Q1 2023 PUR3100 Phase 1 study is underway with data anticipated in Q4 2022 Ends Q2 with $42.9 million in cash and cash equivalents LEXINGTON, Mass., Aug. 8, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NA
- 4y agoPULMPulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute MigrainePR NewswireLEXINGTON, Mass., July 12, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced the d
- 4y agoPULMPulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate UpdatePR NewswireEnds Q1 with $47.5 million in cash and cash equivalents; Extends cash runway into Q2 2024 LEXINGTON, Mass., May 12, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies
- 4y agoPULMPulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate UpdatePR NewswireLEXINGTON, Mass., March 29, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ te
- 4y agoPULMPulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPDPR NewswireLEXINGTON, Mass., March 21, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ techn
- 4y agoPULMPulmatrix Regains Compliance With Nasdaq Listing RequirementsPR NewswireLEXINGTON, Mass., March 17, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ techn
- 4y agoPULMPulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical PipelinePR NewswireLEXINGTON, Mass., March 1, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ techn
- 4y agoPULMPulmatrix, Inc. Announces 1-for-20 Reverse Stock SplitPR NewswireLEXINGTON, Mass., Feb. 24, 2022 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM) a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using
- 4y agoPULMPulmatrix Issues Letter to StockholdersPR NewswireLEXINGTON, Mass., Feb. 1, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technol